<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02236156</url>
  </required_header>
  <id_info>
    <org_study_id>SPL7013-018</org_study_id>
    <nct_id>NCT02236156</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)</brief_title>
  <official_title>A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Determine the Efficacy and Safety of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Starpharma Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Starpharma Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, phase 3 study to determine the efficacy of SPL7013 Gel when administered on
      alternate days for 16 weeks, compared to placebo gel in preventing the recurrence of BV in
      women with a history of recurrent BV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible participants, with both a history of recurrent BV and a current episode of BV, will
      receive a seven-day course of oral metronidazole. Participants who are successfully treated
      for their BV, and continue to be eligible, will be randomly assigned to receive either 1%
      SPL7013 Gel or placebo gel on alternate days at bed-time for 16 consecutive weeks.

      The primary endpoint will be determined at the conclusion of this 16 week treatment phase.

      Participants who experience a BV recurrence will be considered to have completed the study.
      Such participants will receive BV treatment in line with local practice and will not attend
      any further study visits.

      Participants who successfully reach Week 16 without a BV recurrence will enter a 12-week
      follow-up phase to Week 28.

      Participants will attend a study visit at 4-weekly intervals throughout the duration of the
      study to Week 28 (or up to the point of BV recurrence) to assess recurrence of BV and adverse
      events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of BV where a diagnosis of BV is defined as the presence of at least 3 clinical findings</measure>
    <time_frame>At or by the Week 16 visit</time_frame>
    <description>Number of participants with a recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence of BV according to the primary efficacy endpoint definition</measure>
    <time_frame>At or by the Week 28 visit</time_frame>
    <description>Time (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of patient-reported BV symptoms</measure>
    <time_frame>At or by the Week 16 visit</time_frame>
    <description>Number of participants with symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of individual Amsel criteria</measure>
    <time_frame>At or by the Week 16 visit</time_frame>
    <description>Individual Amsel criteria are:
i) Presence of homogenous vaginal discharge characteristic of BV
ii) Positive whiff test
iii) Clue cells representing at least 20% of total epithelial cells
iv) vaginal fluid pH greater than 4.5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of BV as determined by presence of a Nugent score of 7-10</measure>
    <time_frame>At or by the Week 16 visit</time_frame>
    <description>Number of participants with a recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of BV according to the primary efficacy endpoint definition</measure>
    <time_frame>At or by the Week 20, 24 and 28 visits</time_frame>
    <description>Number of participants with a recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of BV according to the composite definition of at least 3 clinical findings and a Nugent score of at least 4</measure>
    <time_frame>At or by the Week 16 visit</time_frame>
    <description>Number of participants with a recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>Study duration</time_frame>
    <description>Number of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responses to Quality of Life (QoL) Questionnaires</measure>
    <time_frame>Screening to Week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">637</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>1% SPL7013 Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole oral tablets 500mg</intervention_name>
    <description>One tablet taken orally twice daily for seven consecutive days</description>
    <arm_group_label>1% SPL7013 Gel</arm_group_label>
    <arm_group_label>Placebo Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% SPL7013 Gel</intervention_name>
    <description>5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.</description>
    <arm_group_label>1% SPL7013 Gel</arm_group_label>
    <other_name>VivaGel</other_name>
    <other_name>astodimer sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo gel</intervention_name>
    <description>5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks</description>
    <arm_group_label>Placebo Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current active episode of BV (diagnosis defined as: at least 3 Amsel criteria; Nugent
             score of at least 4; presence of BV-related symptoms)

          -  History of recurrent BV (at least 3 episodes in previous year including current
             episode)

          -  Using an effective method of contraception

        Exclusion Criteria:

          -  Test positive for a sexually transmitted infection

          -  Presence of genital Herpes Simplex Virus (HSV) lesions or Human Papilloma Virus (HPV)
             lesions requiring treatment

          -  Abnormal pelvic exam, including presence of other vaginal or urinary tract infections

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Paull, PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Starpharma Pty Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Precision Trials, LLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Clinical Research Associates</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyndhurst Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>Plovidiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>Ceske Budejovice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>Pisek</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>Praha 2</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>Vsetin</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>Baja</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>Balatonfured</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>Gyomro</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>Komarom</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>Letavertes</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>Zaporizhzhia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sites Various</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2014</study_first_submitted>
  <study_first_submitted_qc>September 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2014</study_first_posted>
  <disposition_first_submitted>December 4, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>December 4, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 7, 2017</disposition_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

